Method of treating or preventing tumors of the central nervous system

Patent metadata

Field	Value
Publication number	US-10376477-B2
Application number	US-201615376243-A
Country	US
Kind code	B2
Filing date	Dec 12, 2016
Priority date	Apr 4, 2011
Publication date	Aug 13, 2019
Grant date	Aug 13, 2019

Abstract

The invention provides methods and compositions for treatment of a subject with a central nervous system (CNS) tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject exhibits at least one CNS abnormality as a result of the tumor.

First claim

We claim:

1. A method of treating a central nervous system (CNS) tumor in a subject exhibiting at least one CNS abnormality as a result of the presence of the CNS tumor comprising administering to the subject a composition comprising a Coenzyme Q10 (CoQ10) compound, thereby treating the CNS tumor, wherein the at least one CNS abnormality exhibited by the subject as a result of the presence of the CNS tumor comprises difficulty with walking, and treatment of the subject results in amelioration of the difficulty with walking in the subject.

2. The method of claim 1 , wherein the at least one CNS abnormality further comprises a CNS abnormality selected from the group consisting of a headache, a seizure, a change in memory, loss of short term memory, a change in temperament, sudden onset of panic attacks induced by familiar situations, a change in intellectual function, inability to do math, inability to find objects in plain sight; confusion, disorientation, becoming lost in a familiar location; blurred vision, loss of vision, loss of peripheral vision, double vision, dizziness, hearing problems, ringing in ears, buzzing in ears, decreased muscle control, lack of coordination, decreased sensation, weakness, paralysis, paraplegia, quadriplegia, change in gait, difficulty with speech, and balance problems.

3. The method of claim 1 , wherein the at least one CNS abnormality comprises at least 2 CNS abnormalities.

4. The method of claim 1 , wherein the at least one CNS abnormality comprises 3-10 CNS abnormalities.

5. The method of claim 1 , wherein the CoQ10 compound is CoQ10.

6. The method of claim 1 , wherein the tumor is a leukemic tumor.

7. The method of claim 1 , wherein the CoQ10 compound is administered topically.

8. The method of claim 1 , wherein the CoQ10 compound is administered parenterally.

9. The method of claim 1 , wherein the CoQ10 compound is administered by injection or infusion.

10. The method of claim 9 , wherein the CoQ10 compound is not administered directly to the CNS.

11. The method of claim 1 , further comprising administration of an additional agent.

12. The method of claim 11 , wherein the additional agent is a chemotherapeutic agent for treatment of a tumor.

13. The method of claim 1 , wherein the tumor is further treated with radiation therapy.

14. The method of claim 1 , wherein the tumor is further treated with surgery.

15. The method of claim 1 , wherein the subject is human.

16. The method of claim 9 , wherein the CoQ10 compound is provided in an intravenous CoQ10 formulation comprising:
an aqueous solution;
CoQ10 dispersed into a nano-dispersion of particles; and
at least one of a dispersion stabilizing agent and an opsonization reducer;
wherein the nano-dispersion of the CoQ10 is dispersed into nano-particles having a mean particle size of less than 200-nm.

17. The method of claim 16 , wherein the dispersion stabilizing agent is selected from the group consisting of pegylated castor oil, Cremophor EL, Cremophor RH 40, Pegylated vitamin E, Vitamin E TPGS, and Dimyristoylphosphatidyl choline (DMPC).

18. The method of claim 17 , wherein the dispersion stabilizing agent is DMPC.

19. The method of claim 16 , wherein the opsonization reducer is selected from the group consisting of poloxamers and poloxamines.

20. The method of claim 19 , wherein opsonization reducer is poloxamer 188.

21. The method of claim 20 , wherein the dispersion stabilizing agent is DMPC.

22. The method of claim 21 , wherein the CoQ10 formulation has a weight-per-volume of the CoQ10, DMPC and poloxamer 188 of 4%, 3% and 1.5%, respectively.

23. The method of claim 7 , wherein the CoQ10 compound for topical administration is a 3% CoQ10 cream comprising:
(1) a phase A having C12-15 alkyl benzoate at about 4.0% w/w of the composition, cetyl alcohol at about 2.00% w/w of the composition, stearyl alcohol at about 1.5% w/w, glyceryl stearate and PEG-100 at about 4.5% w/w;
(2) a phase B having glycerin at about 2.00% w/w, propylene glycol at about 1.5% w/w, ethoxydiglycol at about 5.0% w/w, phenoxyethanol at about 0.475% w/w, a carbomer dispersion at about 40% w/w, purified water at about 16.7% w/w;
(3) a phase C having triethanolamine at about 1.3% w/w, lactic acid at about 0.5% w/w, sodium lactate solution at about 2.0% w/w, water at about 2.5% w/w;
(4) a phase D having titanium dioxide at about 1.0% w/w; and
(5) a phase E having CoQ10 21% concentrate at about 15.0% w/w.

24. The method of any one of claims 2 , 3 , 4 , 6 , 7 - 9 , 10 , 11 and 12 - 15 , wherein the CoQ10 compound is CoQ10.

Assignees

• Berg Llc

Inventors

• Jimenez Joaquin J
• Narain Niven Rajin
• Sarangarajan Rangaprasad
• Mccook John Patrick

Classifications

• A61P35/04

  specific for metastasis · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P27/16

  Otologicals · CPC title

• A61P27/10

  for accommodation disorders, e.g. myopia · CPC title